Perspectum Partners in a New Study in Singapore for the Early Detection of Liver Cancer using Precision Medicine
Singapore, 4th May 2021 – Perspectum, in collaboration with the National Cancer Centre of Singapore (NCCS) and other partners, launch a landmark study for ea…
4 May 2021
New Study Shows Measurable Organ Impairment in Long COVID Patients
BMJ Open publishes research demonstrating physiological basis for condition OXFORD, ENGLAND, April 26th, 2021 — New research published in BMJ Open outline…
26 Apr 2021
Perspectum Appoints Annalisa Jenkins, MBBS, FRCP to Board of Directors
OXFORD, England, April 22, 2021 – Perspectum, a commercial-stage, precision-health company developing proprietary digital technologies that enable clinicians…
22 Apr 2021
High Liver Fat (Hepatic Steatosis) Linked to Increased Risk of Hospitalization in COVID-19 Patients with Obesity
Breakthrough non-invasive liver imaging helps identify patients at increased risk of severe disease Oxford, UK - March 29th 2021. New research published thi…
29 Mar 2021
LiverMultiScan shown to be the best non-invasive predictor of disease activity in autoimmune hepatitis, demonstrating its potential to influence clinical treatment.
Oxford March 3rd 2021. LiverMultiScan®’s cT1® is the best predictor of autoimmune hepatitis (AIH) disease activity, as shown in a recent publication, which…
3 Mar 2021
Perspectum Lands Top Spot in Alantra Pharma Fast 50 Rankings
Diagnostic imaging company helps providers better assess patient conditions, pursue targeted treatments and achieve greater patient outcomes. OXFORD, UK, Ma…
1 Mar 2021
New research demonstrates superior performance of LiverMultiScan® for identifying patients with NASH and fibrosis
Oxford February 24th 2021. In a new study, Perspectum’s LiverMultiScan® outperformed other markers of liver stiffness for identifying high risk NASH patient…
24 Feb 2021
LiverMultiScan® could be an alternative to liver biopsy for NASH clinical trials.
Oxford, United Kingdom, February 4th, 2021. A recent study demonstrates the potential for non-invasive measures of liver fibro-inflammation and fat, provided b…
4 Feb 2021
UVA Health First Hospital in the State to Offer LiverMultiScan for Non-Invasive Assessment of Liver Disease
CHARLOTTESVILLE, 2 February 2021 – UVA Health is now offering patients a non-invasive liver imaging test, LiverMultiScan, to assess fatty liver disease. P…
2 Feb 2021
World’s First Integrated Imaging Service for Long Covid approved by UK’s MHRA
Oxford, UK, January 14, 2021. The UK’s Medicines & Healthcare products Regulatory Agency (MHRA) approved the use of CoverScan MD, an MRI-based technology…
14 Jan 2021
Perspectum launches study to improve outcomes for patients with liver cancer
14 Jan 2021
FDA awards funding to Perspectum and physicians at Massachusetts General Hospital to accelerate development of imaging biomarkers as drug development tools in liver disease
Dallas, Texas, December 14, 2020 - The Food and Drug Administration (FDA) Center for Drug Evaluation and Research has granted Perspectum funding to accelerate …
14 Dec 2020